Welcome to the Flynn Forum
Education & Training
Patient-focused resources and materials designed to improve decision-making and support service improvement across a number of therapy areas. Developed with clinicians, NHS leaders and the third sector.
About Flynn Pharma
Flynn Pharma is a privately held pharmaceutical company. We are engaged in a wide range of therapy areas including general medicine, NDD, psychiatry, paediatrics, post-operative pain management, anti-infective medicine, women's health, and emergency medicine. Flynn introduces new products, improves existing formulations or adds new indications to benefit patients.
The Flynn Forum engages healthcare professionals from across the clinical setting, offering continued professional development and service improvement through education rich meetings, resource items and service innovations.
Our Community Sites
Your sites for therapy-specific resources, events and details of our products.
Our General Medicine Community
A resource centre for clinicians working across many therapy areas including information and resources regarding treatment and prevention of vitamin D deficiency in adults.
A resource centre for healthcare professionals working in neurodevelopmental disorders such as attention deficit hyperactivity disorder, autism spectrum disorder, and learning disabilities.
Our Women's Health Community
A resource centre for healthcare professionals working in women’s health, including menopause, HRT and contraception.
Become a Flynn Forum Member
Notification of new items added to the community.
Single-click for download, without having to re-enter details.
Option for having hard copies of patient leaflets delivered on request direct to your door.
Use of 'Bookmarks' on items you wish to revist.
Potential involvement in Peer Group Activities.
Personal history of activities downloadable in report form for your CPD.
Request A Meeting
Send a virtual meeting request
Latest Education & Training
Flynn works across a number of complex yet treatable therapy areas and is committed to supporting the continued education of healthcare professionals, trainees and allied roles.
Insomnia in paediatric ASD
4 Reasons to Stop Prescribing Liquid Melatonin for Children
1. European Medicines Agency, Guideline on pharmaceutical development of medicines for paediatric use, 2013. (Accessed November 2022)
Slenyto® (Prolonged release melatonin) Placebo Dose Card
A paediatric dose card illustrating the range of presentations for Slenyto®
To request this material please contact us.
Slenyto® Treatment Goals and Therapy Optimisation – A Guide for Healthcare Professionals
Insomnia in children with ASD is perceived to be one of the most challenging health effects of autism and a successful intervention needs to define realistic and agreed outcomes that can be systematically monitored. This simple guide provides healthcare professionals with a concise summary, including a treatment algorithm, to enable treatment with Slenyto® to be optimised.